Remove companies eqrx-inc
article thumbnail

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

Benzinga

08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. NASDAQ: RVMD ), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. The final votes will be certified by an independent inspector of elections for each company and publicly reported following this certification.

Equity 40
article thumbnail

Revolution Medicines Completes Acquisition of EQRx

Benzinga

09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. NASDAQ: RVMD ), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc. Acquisition Expected to Add Approximately $1.1